Valuation: Polaryx Therapeutics, Inc.

Market Cap 97.2M 86.76M 80.64M 73.35M 138M 9.21B 140M 969M 379M 4.8B 365M 357M 15.37B P/E 2026 *
-10x
P/E 2027 * -6.78x
Enterprise Value 97.2M 86.76M 80.64M 73.35M 138M 9.21B 140M 969M 379M 4.8B 365M 357M 15.37B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
30.08%
Yield 2026 *
-
Yield 2027 * -
1 day-1.02%
1 week-2.50%
Current month-5.80%
1 month-4.65%
3 months-19.09%
6 months-69.81%
1 week 1.88
Extreme 1.88
2.05
1 month 1.86
Extreme 1.8599
2.2
Current year 1.85
Extreme 1.85
48.91
1 year 1.85
Extreme 1.85
48.91
3 years 1.85
Extreme 1.85
48.91
5 years 1.85
Extreme 1.85
48.91
10 years 1.85
Extreme 1.85
48.91
Manager TitleAgeSince
Chief Executive Officer 56 28/02/2023
Director of Finance/CFO 60 31/05/2024
Chief Tech/Sci/R&D Officer 56 31/08/2026
Director TitleAgeSince
Chairman 56 31/05/2021
Director/Board Member 60 31/07/2025
Director/Board Member - 28/01/2026
Date Insider Type Main position Quantity % Market Cap. Importance
27/05/26 Buy

Chief Executive Officer

88,453 0.1868%
18/02/26 Buy

Chief Financial Officer

2,867 -
29/01/26 Other

Chief Financial Officer

225,358 -
Change 5-day change 1-year change 3-year change Capi.($)
-1.02%-2.50% - - 97.2M
+0.21%-4.63%+55.34%+71.32% 68.98B
-1.48%+2.64%+5.12%+59.06% 53.15B
-0.91%+4.61%+9.19%+40.48% 50.83B
+3.45%+4.70%+33.44%+35.96% 44.61B
-2.20%+0.61%+281.88%+532.76% 40.57B
+6.43%+6.84%+18.32%+109.23% 42.53B
+1.28%+1.39%+11.69%+45.10% 30.95B
-0.90%-10.49%+31.48%-1.63% 25.44B
+1.74%-2.02%-13.55%-12.92% 22.66B
Average +0.57%+1.15%+48.10%+97.71% 37.98B
Weighted average by Cap. +0.69%+2.33%+50.35%+102.81%

Financials

2026 *2027 *
Net sales - -
Net income -9.16M -8.18M -7.6M -6.92M -13.01M -868M -13.24M -91.32M -35.73M -453M -34.39M -33.66M -1.45B -16.42M -14.66M -13.63M -12.39M -23.32M -1.56B -23.74M -164M -64.04M -812M -61.64M -60.33M -2.6B
Net Debt - -
Projected Income Statement - Annual - Polaryx Therapeutics, Inc.
Logo Polaryx Therapeutics, Inc.
Polaryx Therapeutics, Inc. is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (LSDs). Its drug candidate pipeline includes PLX-200 (gemfibrozil), PLX-300 (cinnamic acid), PLX-100, and PLX-400. PLX-200 (gemfibrozil), its advanced drug candidate, is an oral small molecule for the treatment of LSDs. PLX-200 is a repurposed drug that the Company is pursuing through a 505(b)(2) regulatory pathway and is designed to be administered through a novel and proprietary oral solution. PLX-300 (cinnamic acid) is a novel, oral small molecule therapy in IND-enabling studies for the treatment of LSDs. PLX-300 is an unsaturated carboxylic acid that occurs naturally in several plants as a deaminated product of phenylalanine. PLX-100 is a preclinical stage orally administrable combination therapy comprised of its PPARa agonist, PLX-200, and vitamin A, a RXRa agonist.
Employees
-
Date Price Change Volume
15/10/26 US$1.950 -1.02% 42,606
14/10/26 US$1.970 +1.55% 16,608
13/10/26 US$1.940 -3.48% 14,920
12/10/26 US$2.010 +0.50% 16,413
09/10/26 US$2.000 0.00% 10,957
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Polaryx Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
1.950USD
Average target price
7.500USD
Spread / Average Target
+284.62%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Polaryx Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. PLYX Stock